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Background: Sox2, a transcription factor and an embryonic stem cell marker, has been implicated in the
pathogenesis of breast cancer (BC). YB-1 is another transcription factor that has been shown to promote
stemness in BC cells.
Methods: Western blotting, quantitative PCR, and siRNAs were used to query the regulatory relationships
between YB-1, Sox2, and their downstream targets. Chromatin immunoprecipitation was used to detect YB-1
interactions at the Sox2 promoter. Mammosphere and soft agar assays were used to assess the phenotypic
consequences of YB-1 knockdown.
Results: Here, we report that YB-1 regulates Sox2. YB-1 was found to bind to the SOX2 promoter and
down-regulate its expression in MCF7 and ZR751. The regulatory interaction between YB-1 and Sox2 was
drastically different between the two phenotypically distinct cell subsets, purified based on their differential
response to a Sox2 reporter. They are referred to as the reporter unresponsive (RU) cells and the reporter
responsive (RR) cells. Upon siRNA knockdown of YB-1, RU cells showed an increase in Sox2 expression but no
change in Sox2 reporter activity; in contrast, RR cells exhibited increased expression and reporter activity of Sox2.
Correlating with these findings, YB-1 knockdown induced a differential response in the expression of genes known
to be regulated by both Sox2 and YB-1 (e.g. CCND1 and ITGA6). For instance, in response to YB-1 knockdown,
CCND1 and ITGA6 expression were decreased or unchanged in RU cells but paradoxically increased in RR cells.
Compared to RU cells, RR cells were significantly more resistant to the suppression of mammosphere formation
due to YB-1 knockdown. Importantly, mammospheres derived from parental MCF7 cells treated with YB-1 siRNA
knockdown exhibited higher expression levels of SOX2 and its downstream targets.
Conclusions: To conclude, in a subset of BC cells, namely RR cells, YB-1 regulates Sox2 to coordinately maintain
stemness and tumorigenic properties.
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Sex-determining region Y-box 2 (Sox2) is a transcription
factor that plays an important role in maintaining pluripo-
tency in embryonic stem cells [1] and in the generation of
inducible pluripotent stem cells [2]. In embryonic stem
cells, Sox2 binds to the promoters of many genes, thereby
transactivating or suppressing their expressions [3]. In* Correspondence: rlai@ualberta.ca.
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unless otherwise stated.normal adult tissues, the expression of Sox2 is largely
restricted to somatic stem cells [4]. In recent years, Sox2
has been found to be aberrantly expressed in cancers,
including those of the lungs, brain, ovaries, bone, colon,
skin and breasts [5-12]. In many of these tumor types,
Sox2 was found in the cancer stem-like cell population
[8,13-16]. Studies using various experimental models have
demonstrated that Sox2 promotes key tumorigenic
properties in cancer cells, including proliferation, inva-
sion, migration, colony formation, non-adherent stem cell-
associated sphere formations in vitro and tumorigenicityd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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to correlate with a worse clinical outcome in cancer
patients [11,18-20]. In breast cancer (BC), aberrant expres-
sion of Sox2 has been found in up to 30% of tumors
[11,15], and in vitro studies have provided evidence that
Sox2 contributes to cell proliferation and mammosphere
formation in BC cell lines [12,15].
Similar to Sox2, Y-box binding protein-1 (YB-1) is a
transcription factor that has been found in embryonic
stem cells, mammary progenitor cells and BC cells
[21-23]. Found in 40% of BC tumors [24], YB-1 is
believed to promote the tumorigenesis of BC, since it
has been shown to enhance mammosphere formation
in vitro, and transcriptionally up-regulate the expres-
sions of a large cassette of stem cell-associated proteins
including CD44, CD49f (α6 integrin), c-Met, EGFR,
Her-2, Cyclin D1, MDR-1, and p110α [22,25-28]. ln
other cell types, it has been shown that YB-1 can also
suppress gene expression, such as those encoding Fas
and granulocyte macrophage colony-stimulating factor
[29,30]. To mediate gene regulation, YB-1 translocates
into the nucleus and interacts with the proximal promoter
regions of its target genes [31,32]. YB-1 is activated by
phosphorylation in its DNA binding domain, and this
biochemical modification confers YB-1 the properties of
nuclear translocation and DNA interactions; Akt, RSK1/2
and GSK3ß kinases have been shown to phosphorylate/ac-
tivate YB-1 [31-33].
Since both YB-1 and Sox2 are important embryonic
stem cell proteins that appear to exert similar biological
effects in BC [1,23], we hypothesized that they may have
important interactions in BC cells. In this regard, we
recently found that total YB-1 and phospho-YB-1Ser102
(a commonly used surrogate marker of YB-1 activation)
are expressed in MCF7 and ZR751, two Sox2-expressing
BC cell lines. In this study, we found evidence that YB-1
regulates the expression of Sox2. Importantly, YB-1
exerted different biological effects in the distinct pheno-
typically distinct cell subsets, separated based on their
differential responsiveness to a Sox2 reporter, namely
reporter responsive (RR) cells and reporter unresponsive
(RU) cells [16]. The biological implications of our find-
ings will be discussed, particularly in the context that RR
cells have been previously shown to be more tumori-
genic and stem-like as compared to RU cells [16].
Methods
Cell lines, cell culture, and reagents
Parental breast cancer cell lines ER +MCF7, ZR751, and
ER- MDA-MB-231 were purchased from American Type
Culture Collection (ATCC, Rockville, MD). The Unsorted,
RU, and RR cell lines are derived as previously described
[16]. The Unsorted cells refer to parental cells stably
infected with the Sox2 reporter while RU and RR cellshave been purified based on GFP expression [16]. Since
the Sox2 reporter carries dual genes encoding both lucif-
erase and green fluorescence protein (GFP), RR cells but
not RU cells stably show luciferase activity and GFP ex-
pression over time [16]. RU and RR cells are maintained
and culture separately for our studies, and keep their dis-
tinct phenotypes [16]. All the above mentioned cell lines
were maintained in high glucose Dulbecco’s Modified
Eagle Medium (DMEM) (Life Technologies, Grand
Island, NY) supplemented with 10% fetal bovine serum
(FBS) (Life Technologies). LY294002 (#L9908, Sigma-
Aldrich Canada, Oakville, ON, Canada), SL0101 (#559285,
Calbiochem, EMD Millipore Corporation, Billerica, MA),
and CHIR99021 (#361559, Calbiochem) were solubilized
in DMSO. Insulin-like growth factor-1 (IGF-1) (#I3769,
Sigma-Aldrich) was solubilized in phosphate buffered
saline (PBS).
Western blotting
Western blot analyses were performed as previously
described [16]. All antibodies were diluted in 5% bovine
serum albumin (BSA) in Tris buffered saline and 0.1%
Tween-20 (TBST): anti-Sox2 (1:500, #2683-1), and anti-
total YB-1 (1:100,000, #2397-1) were purchased from
Epitomics, Burlingame, CA. Anti-phospho-YB-1Ser102
(1:500, Cat. #2900), anti-phospho-Akt (1:1000, #9271),
anti-total Akt (1:1000, #9272), and anti-vinculin (1:1000,
#4650) were purchased from Cell Signaling Technolo-
gies, Danvers, MA. The expression of vinculin served as
the loading control for all western blots.
siRNA knockdown of YB-1
Two siRNA species, #1 and #2 (corresponding to
SI03019191 and SI04172007 respectively, Qiagen Canada,
Toronto, Ontario, Canada), were used to knockdown
YB-1. The use of scrambled siRNA (ON-TARGETplus
Non-targeting Pool, #477C20, Dharmacon, Thermo-
Scientific, Waltham, MA) served as the negative control.
For each reaction, 40 pmol of siRNA (20 nM final con-
centration) and 5 μL of Lipofectamine RNAiMAX (Life
Technologies) were added to 0.5 mL of OptiMEM media
(Life Technologies), and 800,000 cells in normal culture
medium in 6-well plates were reverse transfected. Cells
were incubated with siRNAs for 72 or 96 hours before
harvesting. We have employed the use of 2 unique siRNA
sequences targeted against YB-1. We have primarily used
YB-1 siRNA#1 throughout the study as we have achieved
successful and consistent knockdowns with this sequence
in our laboratory and previous work done by the first
author [25]; as well it is the recommended validated
sequence from the manufacturer. We have incorporated
the use of YB-1 siRNA#2 in our study to validate the
findings of YB-1 siRNA#1. In the mammosphere culture
condition, we found that the YB-1 siRNA#2 sequence
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10 days post-transfection and thus we reported the results
using the YB-1 siRNA#2 sequence. YB-1 siRNA denotes
YB-1 siRNA #1 throughout the manuscript and figures.
Chromatin immunoprecipitation (ChIP)
ChIP protocol was performed as previously described
[16]. Anti-total YB-1 antibody (same as for western blot-
ting) was used at 5 μg per immunoprecipitation. Normal
IgG rabbit antibody was used at 5 μg per immunoprecipi-
tation (#2729, Cell Signaling Technologies). ChIP primers
sequences were: Sox2 (a): Forward (F) – GAGAGAAA
AAGGAGAACCTTCG, Reverse (R) – ACGGTGCATTG
TTTTGTTCC; Sox2 (d): F – CCCAACAAGAGAGTGG
AAGG, R – ATTTTAGCCGCTCTCCCATT.
RNA extraction, cDNA synthesis, quantitative reverse
transcriptase PCR (q-RT-PCR)
Total RNA extraction was performed with the Qiagen
RNeasy Kit (Qiagen Canada) according to the manufac-
turer’s protocol. Briefly, 1 μg of RNA was reverse tran-
scribed using Superscript II (Life Technologies) according
to the manufacturer’s protocol. 1 μL of the resulting
cDNA mixture was added to the Platinum SYBR Green
qPCR SuperMix-UDG with Rox (Life Technologies) and
amplified with target gene specific primers. Primers
sequences, Sox2: F – ACAACTCGGAGATCAGCAA, R –
GTTCATGTGCGCGTAACTGT; Nanog: F – CTCCAA
CATCCTGAACCTCAGC, R – CGTCACACCATTGCT
ATTCTTCG; CD49f: F – ATGCACGCGGATCGAGTTT,
R – TTCCTGCTTCGTATTAACATGCT; Cyclin D1: F –
GCTGCGAAGTGGAAACCATC, R – CCTCCTTCTGC
ACACATTTGAA; EGFR: F – GTGACCGTTTGGGA
GTTGATGA, R – GGCTGAGGGAGGCGTTCTC; Her2:
F – GGGAAGAATGGGGTCGTCAAA, R – CTCCTCCC
TGGGGTGTCAAGT. All genes of interest are normalized
to GAPDH transcript expression levels, sequence as previ-
ously described [16].
Luciferase assay
The Luciferase Assay System (#E4530, Promega, Corpor-
ation, Madison, WI) was performed according to the
manufacturer’s protocol, plated on Costar white poly-
styrene opaque 96-well plates (#3912, Corning, Corning,
NY) and analyzed on the FLUOstar Omega multi-mode
microplate reader (BMG Labtech, Ortenburg, Germany).
Flow cytometry
Flow cytometry analyses were performed as previously
described [16].
Mammosphere assay
Mammospheres were seeded and cultured as previously
described [16]. Briefly, cells were trypsinized and passedthrough a 40 μm cell strainer (BD, Franklin Lakes, New
Jersey) and seeded into ultra-low adherent plates (Corning)
in Mammocult media (StemCell Technologies, Vancouver,
BC, Canada). For subsequent RNA extractions, mammo-
spheres were isolated and collected by centrifugation as
per manufacturer’s protocol.
Soft agar colony formation assay
20% 2X DMEM was mixed at a 1:1 ratio with a 1.4%
agarose solution (0.7% final concentration) and seeded at
400 μL/well into a 24-well plate. 10,000 cells were mixed
with 200 μL 20% 2X DMEM and mixed with 200 μL
0.7% agarose solution (0.35% final concentration) and
seeded atop the bottom agarose layer. 10% DMEM media
was added on top and changed weekly. Colonies were
counted at 14 days.
Statistical Analyses
Paired Student’s T-tests were used for statistical analyses
of experiments throughout, where p < 0.05 is denoted
by *, and p < 0.01 is denoted by **. All graphs represent
the average of at least 2 independent experiments with
triplicates. The error bars represent the standard error of
the mean.
Results
YB-1 negatively regulates Sox2 expression in breast cancer
We first examined if Sox2 expression can be regulated
by YB-1. As shown in Figure 1A, we found that siRNA
knockdown of YB-1 induced a substantial increase in
Sox2 protein expression in parental MCF7 and ZR751,
two Sox2-expressing and estrogen receptor (ER)-positive
BC cell lines. As we recently discovered that MCF7 and
ZR751 are composed of two phenotypically distinct cell
subsets that can be separated based on their differential
response to a Sox2 activity reporter [16], we asked if
YB-1 interacts with Sox2 differently in these two cell
subsets, namely RU and RR cells. SiRNA knockdown
of YB-1 effectively induced an up-regulation of Sox2
protein expression in both RU and RR cells (Figure 1B). In
both the “Unsorted” MCF7 and ZR751 cells, YB-1 knock-
down also induced an up-regulation of Sox2 protein
expression (Figure 1C). The “Unsorted” cells are the
parental cells that have been stably infected with the
Sox2 reporter but have not been purified or sorted
into RU and RR cells.
It has been previously shown that phospho-YB-1Ser102,
a surrogate marker of its activation [31,32], is elevated in
ER-negative BC [22] than ER-positive BC. Based on our
observation that YB-1 down-regulates Sox2, we then
predicted that ER-negative BC expresses a lower level of
Sox2 than ER-positive BC, due to their higher YB-1 activ-
ity. Based on the previously published gene array studies
using 50 BC cell lines [34], we found that the expression
Figure 1 YB-1 negatively regulates Sox2 protein expression in breast cancer cells. (A) Western blot of total YB-1 and Sox2 protein expression
in MCF7 and ZR751 parental and (B) MCF7 and ZR751 RU, RR, and (C) Unsorted cells after 72-hour treatment of scrambled or YB-1 siRNA at 20 nM,
denoted by siScr and siYB-1.
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(Additional file 1: Figure S1). Moreover, in our own
study including a small cohort of BC cell lines [16],
we did observe a higher Sox2 protein expression in
ER-positive cells lines. Taken together, these observa-
tions further support that the YB-1 is a negative regulator
of Sox2 in BC.
We also asked if Sox2 regulates YB-1. As shown in
Additional file 1: Figure S2, siRNA knockdown of Sox2
in MCF7 and ZR751 did not result in any detectable
change in the protein expression of total YB-1 or
phospho-YB-1Ser102.
YB-1 binds to the SOX2 promoter and regulates Sox2
expression
To examine if YB-1 regulates Sox2 at the transcriptional
level, we searched the proximal promoter region of SOX2
(−1 to −2.5 kb upstream of the transcription start site) for
the minimal consensus sequence that confers YB-1 bind-
ing, ATTG/CAAT [31]. We identified 10 putative YB-1
binding sites in the SOX2 promoter (Figure 2A). Using
chromatin immunoprecipitation (ChIP) and primers de-
signed to flank these YB-1 putative binding sites, we found
evidence that YB-1 binds to the SOX2 promoter at two
adjacent regions (Figure 2B). Further, promoter DNA
binding by YB-1 was detectable in both RU and RR cells
derived from MCF7 and ZR751 cells (Figure 2B). To fur-
ther support that YB-1 regulates Sox2 at the transcrip-
tional level, we found that the SOX2 mRNA transcripts
were significantly upregulated in response to siRNA
knockdown of YB-1 in both RU and RR cell populations
derived from MCF7 and ZR751 (Figure 2C). We alsodetected this phenomenon in MDA-MB-231, an ER-
negative BC cell line (Additional file 1: Figure S3).
Activation of YB-1 suppresses Sox2 expression
To address if YB-1 activation, as evidenced by phosphor-
ylation at its serine-102 residue [31,32], modulates Sox2
expression, we treated MCF7 cells with a small molecule
(LY294002) that inhibits activation of Akt, a kinase previ-
ously shown to directly phosphorylate YB-1 [31]. As shown
in Figure 3A, increasing concentrations of LY294002
down-regulated phospho-YB-1Ser102 in a dose-dependent
manner and increased the SOX2 mRNA transcript levels in
both RU and RR cells. The same results were obtained with
SL0101 and CHIR99021, two small molecule inhibitors of
two other direct upstream YB-1 kinases/activators, p90
ribosomal S6 kinase (RSK) 1/2 and glycogen synthase
kinase 3-beta (GSK3ß), respectively [32,33] (Figure 3B).
Further, we were able to detect an increase in Sox2 protein
expression when MCF7 cells were treated for 72 hours
with the superiorly stable GSK3ß inhibitor, CHIR99021
(Figure 3C). Conversely, increasing concentrations of
insulin-like growth factor-1 (IGF-1), an activating growth
factor of the PI3K/Akt/YB-1 pathway, elevated phospho-
YB-1Ser102 and led to decreased Sox2 protein expression
(Figure 3D). These findings support the concept that the
activation status of YB-1 is important in regulating Sox2
expression in BC cells.
YB-1 regulates the Sox2 reporter activity only in the RR
cell subset
Next, we asked if the Sox2 reporter activity is also regu-
lated by YB-1. Unsorted cells derived from MCF7 and
Figure 2 YB-1 binds to the SOX2 promoter and regulates Sox2 transcripts. (A) Schematic diagram of the Sox2 proximal promoter (2.5 kb
upstream of transcriptional start site, denoted by +1) with markings of the minimal YB-1 consensus sequence ATTG/CAAT. Sox2 promoter ChIP
primers designed against putative binding sites are shown. (B) MCF7 and ZR751 RU and RR ChIP DNA agarose gel results of DNA sequences
immunoprecipitated by normal rabbit IgG or a rabbit anti-human YB-1 antibody amplified by Sox2 promoter specific primers a and d. MCF7 Input
and ZR751 Input represent the DNA isolated from chromatin before immunoprecipitation to show equal input amounts. (C) Quantitative-RT-PCR
results illustrating Sox2 mRNA transcript levels after 72-hour 20nM YB-1 siRNA treatment. Western blot shows YB-1 knockdown efficiency.
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significantly increased luciferase activity in response to
YB-1 siRNA knockdown (Figure 4A). When we performed
the same experiment using purified RU and RR cells,
we found that YB-1 knockdown induced luciferase ac-
tivity and GFP expression in the RR cells (Figure 4B
and C). The small increase seen in the MCF7 RR
cells (Figure 4B) could be due to the innately high lu-
ciferase activity in that cell population. In contrast, the
luciferase activity and GFP expression of RU cells re-
mained barely detectable after siRNA knockdown of YB-1(Figure 4B and C), despite a substantial increase in Sox2
protein (Figure 1B).
YB-1 knockdown induces differential gene expression
patterns in RU and RR cells
As we have demonstrated that YB-1 can increase the Sox2
reporter activity in RR but not RU cells, we questioned if
this difference may result in differential regulation of Sox2
downstream target genes between these two cell subsets,
which may contribute to their phenotypic differences. To
address this question, we selected a panel of genes that are
Figure 3 Activation of YB-1 suppresses Sox2 expression. Western blots depicting (A) altered PI3K/Akt/YB-1 signaling after 0, 10, or 30 μM
treatments of LY294002 (PI3K inhibitor) for 6 hours, (B) altered YB-1 phosphorylation after 24-hour treatments of 50 μM SL0101 (RSK1/2 inhibitor)
and 10 μM CHIR99021 (GSK3ß inhibitor), (C) Sox2 protein expression after 72-hour treatment of 10 μM CHIR99021, and (D) altered PI3K/Akt/YB-1
signaling after 6-hour 0, 25, or 100 ng/mL IGF-1 stimulations in MCF7 RU and RR cells. Accompanying q-RT-PCR graphs of SOX2 transcript levels
are shown. DMSO only treatments were used as vehicle controls except for D where PBS only treatments were used.
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Figure 4 YB-1 regulates the Sox2 transcription reporter activity only in the RR cell subset. (A) Luciferase assay results of Sox2 reporter
luciferase activity in MCF7 Unsorted cells (with natural proportions of RU and RR cells) after 72-hour treatments of scrambled or 2 unique YB-1
siRNAs at 20 nM. (B) Luciferase assay data showing Sox2 reporter luciferase activity relative to the RU siRNA treatment luciferase value and (C) flow
cytometry analyses of Sox2 reporter GFP expression in MCF7 and ZR751 RU and RR cells after 72-hour 20 nM scrambled or YB-1 siRNA treatments.
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Sox2. For genes that have been shown to be up-regulated
by Sox2 but not YB-1, such as NANOG [35], YB-1 knock-
down is expected to result in no detectable change in
NANOG expression in RU cells, since the Sox2 reporter
activity is undetectable in these cells. In contrast, the same
experimental manipulation, which resulted in a compen-
satory increase in Sox2 expression and activity in RR cells,
is expected to up-regulate the expression of NANOG. In
keeping with this concept, the expression level of NANOG
did not change appreciably in response to YB-1 knock-
down in RU cells derived from MCF7 and ZR751 cells;
in contrast, the same treatment resulted in a significantincrease in the NANOG expression level in RR cells
derived from the two cell lines (Figure 5A). To further
show that increased Sox2 protein expression induces Sox2
activity in the MCF7 cells despite a marginal increase as
detected by luciferase (Figure 4B), we overexpressed Sox2
in RU and RR cells derived from MCF7, and detected an
increase expression of the NANOG transcripts only in the
RR cells (Figure 5B).
For genes that are known to be up-regulated by both
YB-1 and Sox2, such as CCND1 (Cyclin D1) [12,36] and
ITGA6 (CD49f) [25], YB-1 knockdown is expected to
decrease the expression of these two genes in RU cells; in
contrast, YB-1 knockdown should result in a compensatory
Figure 5 (See legend on next page.)
Jung et al. BMC Cancer 2014, 14:328 Page 8 of 13
http://www.biomedcentral.com/1471-2407/14/328
(See figure on previous page.)
Figure 5 YB-1 knockdown induces different gene expression patterns in RU and RR cells. (A) Quantitative-RT-PCR analyses of relative
mRNA transcripts of Sox2 only target NANOG in MCF7 and ZR751 RU and RR cells after scrambled or YB-1 siRNA treatment at 20 nM for 72 hours.
(B) MCF7 RU and RR cells were transfected with 3 μg of pcDNA3-Flag-Empty Vector (EV) or pcDNA3-Flag-Sox2 and harvested for mRNA after
72 hours. Q-PCR analyses was performed using primers designed against SOX2 and NANOG. SOX2 transcript levels are normalized to the Flag-EV
transfections. Accompanying Flag western blot is shown. (C) Quantitative-RT-PCR analyses of Sox2 and YB-1 targets CCND1 (Cyclin D1), and ITGA6
(CD49f) in MCF7 and ZR751 RU and RR cells after scrambled or YB-1 siRNA treatment at 20 nM for 72 hours and (D) accompanying western blot
showing YB-1, Sox2 and Cyclin D1 protein expression.
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RR cells should sustain or increase the expressions of these
genes. In keeping with this concept, the transcript
levels of both CCND1 and ITGA6 were decreased or
stayed the same in RU cells in response to YB-1 knock-
down (Figure 5C), and the levels of CCND1 and ITGA6
were elevated after YB-1 knockdown in RR cells (Figure 5C,
Additional file 1: Figure S4). Correlating with our mRNA
data, western blotting showed that YB-1 knockdown de-
creased Cyclin D1 protein expression in RU cells derived
from both cell lines, whereas the treatment induced no
appreciable change in the protein expression of Cyclin D1
in RR cells (Figure 5D).
Up-regulation of Sox2 and its downstream targets is
accompanied by enhanced tumorigenic properties in
YB-1 down-regulated RR cells
Next, we asked if RU and RR cells exhibit differential
phenotypes in response to YB-1 down-regulation. It has
been previously reported that YB-1 knockdown can sig-
nificantly decrease mammosphere formation in BC cells
[25]. We found similar findings for MCF7 and ZR751
after siRNA knockdown of YB-1; the reduction for MCF7
was approximately 50% (Figure 6A) and that for ZR751
was approximately 20% (Additional file 1: Figure S5).
Using our sorted RU and RR cells derived from MCF7, we
found that YB-1 knockdown reduced the number of
mammospheres and soft agar colonies formed in RR cells
significantly less efficiently (20% reduction) as compared
to RU cells (40% reduction) (Figure 6B). Similar findings
were observed for ZR751 (Additional file 1: Figure S5).
Pictures of MCF7 mammospheres and soft agar are shown
in Additional file 1: Figure S6.
To test if the lesser impact of YB-1 knockdown on the
mammosphere formation of RR cells is directly related
to the compensatory increase in Sox2 expression and
activity in these cells, we collected the mammospheres
derived from RU and RR cells treated with YB-1 siRNA.
As shown in Figure 6C, we observed an increase in lucif-
erase activity in the remaining mammospheres after YB-1
knockdown derived from RR cells but not RU cells
(Figure 6C). Further, we analyzed the gene expression
of the collected mammospheres derived MCF7 ‘Un-
sorted’ cells treated with YB-1 siRNA. As shown in
Figure 6D, we found significantly increased expressionlevels of SOX2, NANOG, CCND1 and ITGA6 in these
cells, a pattern that is similar to that of RR cells treated
with YB-1 siRNA (Figure 5). Parallel findings were obser-
ved for MCF7 parental cells (Additional file 1: Figure S7).
Discussion
While the functional importance of Sox2 in embryonic
stem cells is well characterized, the biological signifi-
cance of Sox2 in cancer has not been extensively studied.
Sox2 expression is well characterized in embryonic stem
cells [1], where Sox2 is regulated by the Wnt, BMP, and
JAK-STAT signaling pathways [1]. Aberrant expression
of Sox2 in cancer cells has been well documented in a
number of tumor types, but the mechanisms underlying
this biochemical aberrancy is largely unexplored. In BC,
there is evidence that Sox2 carries biological significance
[11,12,15], although how Sox2 overexpression is regu-
lated in this cell type is unknown. We hypothesized that
YB-1, another transcription factor important in stem cell
biology and the pathogenesis of BC [22,25,37], regulates
Sox2 in BC cells.
Our findings led us to conclude that YB-1 regulates
the expression of Sox2 in BC, likely at the transcriptional
level. This conclusion is supported by our observations
that knockdown of YB-1 substantially up-regulated the
SOX2 transcripts and protein expression in MCF7 and
ZR751. Furthermore, using the ChIP assay, we also found
evidence that YB-1 interacts with the proximal promoter
of SOX2, which contains multiple YB-1 binding consensus
sequences. We were surprised with the finding that YB-1
negatively regulates Sox2, since a previous report has
described a positive correlation between YB-1 and Sox2 in
glioma cells [37]. It is likely that the regulatory relation-
ship between these two important stem cell transcription
factors is complex and the discrepancy between positive
or negative regulation is cell type-specific.
Our data also led us to conclude that activation of
YB-1, as evidenced by the phosphorylation of YB-1 at
serine-102, is required to regulate Sox2 expression.
Specifically, down-regulation of YB-1 activation by serine
phosphorylation at residue 102 by the treatment of phar-
macologic inhibitors effectively increased Sox2 expression.
The concept that activated YB-1 can suppress Sox2
expression correlates well with the previous observations,
in which YB-1 phosphorylation at the serine-102 residue
Figure 6 Up-regulation of Sox2 and its downstream targets is accompanied by enhanced tumorigenic properties in YB-1 down-regulated
RR cells. (A) Mammosphere assay formation efficiency of MCF7 Unsorted cells after 72-hour 20 nM of scrambled or YB-1 siRNAs. (B) Mammosphere
and soft agar colony forming efficiency of MCF7 RU and RR cells after 72-hour 20 nM of scrambled or YB-1 siRNAs. (C) Luciferase assay results of
collected MCF7 RU and RR 7-day mammospheres formed after 72-hour 20 nM of scrambled or YB-1 siRNAs normalized to the RU cells siScr treatment
luciferase value. (D) Mammosphere assay formation efficiency of MCF7 Unsorted cells after 72-hour 20 nM treatment of scrambled or YB-1 siRNA #2,
and accompanying quantitative-RT-PCR analyses of relative mRNA transcripts of YBX1 (YB-1), SOX2, NANOG, CCND1 (Cyclin D1), and ITGA6 (CD49f) from
resulting mammospheres after 7-day mammosphere culture and previous 72-hour 20 nM scrambled or YB-1 siRNA #2. YB-1 siRNA #2 was used here as
it showed superior knockdown efficiency in the 7-day mammosphere culture conditions.
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control over its downstream gene targets, many of which
are stem cell genes [22,25]. This concept also correlates
with the previous findings that YB-1 activation, known to
be mediated by kinases such as Akt, RSK1/2, and GSK3ß,
confers its ability to translocate to the nucleus, bind to
various gene promoters, and regulate their expression in
both ER- positive and negative BC cells [31-33]. While we
understand that our experiments in this study involves the
use of pharmacologic inhibitors that carry some degree of
non-specificity, results of these studies are in parallel with
those derived from studies using YB-1 siRNAs.
Based on our findings that YB-1 suppresses the ex-
pression of Sox2 in BC, and the previous observation
that ER-negative BC cell lines generally have a higher
level of YB-1 activation (phosphorylation of YB-1 at
serine 102) than ER-positive BC cell lines [22], we spec-
ulated that the expression level of Sox2 is higher in
ER-positive BC cells. To this end, we reviewed published
cDNA gene expression microarray data collected from acomprehensive panel of 50 BC cell lines [34]. Indeed, we
found that ER-positive BC cell lines expressed a signifi-
cantly higher SOX2 expression than ER-negative cell lines
(Additional file 1: Figure S1). Similar observations were
made in our previously published study using western
blotting [16]. Of note, other YB-1 positively regulated
genes such as CD44, MET, and EGFR are likewise previ-
ously reported to be highly expressed in ER-negative BC
compared to ER-positive BC [38]. Further, in support that
YB-1 also suppresses Sox2 expression in ER-negative BC,
we demonstrated that YB-1 knockdown increased Sox2
expression in MDA-MD-231, an ER-negative BC cell line
(Additional file 1: Figure S3).
While Sox2 protein expression was negatively regulated
by YB-1 in both ER-positive BC cell lines in our studies, it
appears that YB-1 only regulates Sox2 transcription activ-
ity in a small subset of these cells. Specifically, we found
that the siRNA knockdown of YB-1 resulted in increased
luciferase and GFP expression in the RR cell subset (in
monolayer and in mammosphere culture) but not the RU
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Sox2 protein level in RU cells after YB-1 knockdown failed
to induce detectable Sox2 transcription activity is in keep-
ing with our previous observation, in which enforced
expression of Sox2 in MCF7 and ZR751 using an retro-
viral Sox2 expression vector also failed to induce detect-
able Sox2 transcription activity [16]. Thus, it appears that
RU and RR cells are inherently biologically different. The
mechanisms underlying this phenotypic difference be-
tween these two cell subsets are currently under active
investigation in our laboratory.
The drastic difference in the relationship between YB-1
and Sox2 in the two cell subsets of BC is expected to
result in substantial biochemical differences, which likely
underlie the phenotypic differences between RU and RR
cells described previously by our group [16]. In this re-
gard, differential results from our gene expression analyses
in the RU and RR cell populations after YB-1 knockdown
support this view. Specifically, following YB-1 knockdown,
stem cell genes NANOG and ITGA6 (CD49f ) were
unchanged or down-regulated in RU cells but up-
regulated in RR cells. Our results strongly suggest that,
with inhibition of YB-1, RU and RR cells will undergo
dramatically different biochemical changes, with the stem
cell-associated genes being unchanged or suppressed in
RU cells whereas the expressions of these genes in RR
cells are increased or sustained due to the compensatory
increase in Sox2 expression and transcription activity.
Correlating with these observations, we observed that
the efficiency of mammosphere formation remained
relatively high in RR cells after YB-1 siRNA knockdown.
Based on our findings, it is tempting to speculate that
the higher efficiency of mammosphere formation in RR
cells after YB-1 knockdown is due to the increased Sox2
transcription activity and the sustained expression of
various Sox2 downstream target genes in these cells. In
parallel with these findings, we showed that the mam-
mospheres derived from Unsorted and parental MCF7
cells treated with YB-1 knockdown exhibited a similar
gene expression pattern of RR cells treated with YB-1
knockdown, with high expression levels of SOX2, NANOG,
CCND1 and ITGA6.
The existence of tumor heterogeneity, as highlighted
by RU and RR cell subsets in our models, may provide
explanations to tumor resistance to cancer treatments.
Based on the concept generated from this current study,
treatments that result in YB-1 inhibition in cancer cells
may up-regulate Sox2 expression and transcription activity
in the RR cell subset. As a result, stem cell-related genes
and possibly the stem cell phenotype can be increased or
sustained in this small cell subset, leading to their persist-
ent survival during the course of cancer treatment. Dir-
ectly relevant to our discussion, at the time of writing, we
are aware of an on-going NIH/NCI clinical trial examiningthe efficacy of Akt inhibitor MK2206 in BC patients.
MK2206, like LY294002 inhibits Akt phosphorylation/ac-
tivation, and we hypothesize that the inhibition of phos-
phorylation of YB-1 at Ser-102 will up-regulate Sox2
expression.
Conclusions
In summary, we have characterized a novel regulatory
relationship between YB-1 and Sox2, two important can-
cer and/or stem cell transcription factors that have been
implicated in the pathogenesis of BC. In addition, in the
context of the inherent dichotomy of BC cells (i.e. RU
and RR cells), YB-1 contributes to the phenotypic hetero-
geneity between the cell subsets by mediating differential
gene regulation of Sox2 downstream targets. This level of
tumor heterogeneity may underline some of the mecha-
nisms of drug resistance in BC.
Additional file
Additional file 1: Figure S1. Sox2 is expressed higher in ER-positive
breast cancer cell lines. Published gene expression microarray data from
50 BC cell lines reveals relative average Sox2 expression levels with
respect to estrogen receptor status. Figure S2. Sox2 does not modulate
YB-1 expression or phosphorylation at serine-102. Western blot of Sox2,
phospho-YB-1Ser102, and total YB-1 protein expression in MCF7 and ZR751
RU and RR cells after 72-hour 20nM scrambled or Sox2 siRNA treatments.
Figure S3. YB-1 knockdown increases Sox2 transcript levels in ER-MDA-
MB-231 cells. Quantitative-RT-PCR analyses of SOX2 mRNA in MDA-MB-231
RU and RR cells after 72-hour 20 nM scrambled or YB-1 siRNA treatments.
Figure S4. YB-1 siRNA #2 treatments result in up-regulation of SOX2 and
CCND1. Quantitative-RT-PCR analyses of relative CCND1, YBX1, and SOX2
mRNA in MCF7 RU and RR cells after 72-hour 20 nM scrambled or YB-1
siRNA #2 treatments. Figure S5. ZR751 RR cells form more mammospheres
after YB-1 knockdown compared to ZR751 RU cells. Mammosphere assay
formation efficiency of ZR751 Unsorted, RU, and RR cells after 72-hour
20 nM scrambled or YB-1 siRNA treatments. Figure S6. Mammospheres and
soft agar colonies photographs after YB-1 knockdown in MCF7 RU and RR
cells. Mammosphere assay formation (Day 7) and soft agar colony formation
(Day 14) of MCF7 RU and RR cells after 72 hour treatments of 20 nM
scrambled or YB-1 siRNAs. Figure S7. Mammospheres derived from YB-1
down-regulated MCF7 Parental cells show up-regulation of SOX2 and other
targets. Mammosphere assay formation efficiency of MCF7 Parental cells
after 72-hour 20 nM scrambled or YB-1 siRNA #2 treatments, and
quantitative-RT-PCR analyses of YBX1 (YB-1), SOX2, NANOG, CCND1, and
ITGA6 mRNA from resulting mammospheres after 7-day mammosphere
culture and 72-hour 20 nM scrambled or YB-1 siRNA #2. YB-1 siRNA #2 was
used here for superior knockdown efficiency in the 10-day assay.
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